Thu Sep 19 08:23:42 UTC 2024: ## Rhumbline Advisers Increases Stake in Ironwood Pharmaceuticals

**BOSTON, MA – September 19, 2024** – Rhumbline Advisers, a prominent investment firm, has increased its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 0.7% during the second quarter, according to a recent Form 13F filing with the SEC. The fund now owns 365,701 shares of the biotechnology company, valued at $2,384,000.

Rhumbline Advisers isn’t the only institutional investor making moves with Ironwood. Vanguard Group Inc. significantly boosted its stake by 21.8% in the first quarter, now owning 19,521,366 shares valued at $170,031,000. Other notable investors include Armistice Capital LLC, which increased its holdings by 64.9% in the fourth quarter, and Jacobs Levy Equity Management Inc., who saw their stake grow by 40.8% in the first quarter. Newcomers Kynam Capital Management LP also entered the market, acquiring a new stake worth $14,154,000 in the first quarter.

Analysts are divided on the stock’s future. StockNews.com upgraded Ironwood to a “buy” rating in July, while Capital One Financial downgraded it to “equal weight” in August. Leerink Partners initiated coverage with a “market perform” rating, while Wells Fargo & Company maintained an “overweight” rating but lowered their price target. Currently, the stock holds a “Moderate Buy” consensus rating with an average price target of $13.57.

Ironwood Pharmaceuticals, a healthcare company, develops and commercializes gastrointestinal (GI) products. The company markets linaclotide, a drug for treating irritable bowel syndrome with constipation and chronic idiopathic constipation, under the LINZESS and CONSTELLA brands in various markets.

**About Ironwood Pharmaceuticals**

Ironwood Pharmaceuticals, Inc. is a leading developer and commercializer of innovative therapies for gastrointestinal disorders. The company’s mission is to improve the lives of patients with GI diseases through the development of novel, effective, and well-tolerated therapies. Ironwood is headquartered in Cambridge, Massachusetts.

**Disclaimer:** This article is for informational purposes only and should not be considered as investment advice. Please consult with a financial professional before making any investment decisions.

Read More